Eli Lilly (NYSE:LLY) reported positive Phase 3 data from its BRUIN CLL-321 study of its drug pirtobrutunib, also known as Jaypirca, in the treatment adult patients with chronic lymphocytic leukemia, or CLL, or small lymphocytic lymphoma, or SLL, previously treated with a covalent BTK inhibitor.